Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 8/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13224856 | 1.00 | PTGS2 (0.36) | PTGS2MAOBHTR2AHTR2CHTR2B | |
| SCHEMBL13224854 | 1.00 | PTGS2 (0.36) | PTGS2MAOBHTR2AHTR2CHTR2B | |
| SCHEMBL8927314 | 1.00 | PTGS2 (0.36) | PTGS2MAOBHTR2AHTR2CHTR2B | |
| SCHEMBL13224837 | 1.00 | PTGS2 (0.36) | PTGS2MAOBHTR2AHTR2CHTR2B | |
| SCHEMBL6003460 | 0.83 | OPRM1 (0.37) | MAOBOPRM1MAOA | |
| SCHEMBL6003710 | 0.83 | OPRM1 (0.37) | MAOBOPRM1MAOA | |
| SCHEMBL13224947 | 0.83 | OPRM1 (0.37) | MAOBOPRM1MAOA | |
| SCHEMBL4080962 | 0.83 | OPRM1 (0.37) | MAOBOPRM1MAOA | |
| SCHEMBL11133978 | 0.82 | HTR2C (0.36) | MAOBHTR2AHTR2CHTR2BOPRM1 | |
| SCHEMBL28468651 | 0.82 | HTR2C (0.50) | MAOBHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289744-A1 | PROCESS FOR PREPARING OPTICALLY PURE MILNACIPRAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | ARCH PHARMALABS LIMITED (IN) | 2012-11-15 | — | — | US | disclosed |
| US-20120289744-A1 | PROCESS FOR PREPARING OPTICALLY PURE MILNACIPRAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | ARCH PHARMALABS LIMITED (IN) | 2012-11-15 | — | — | US | disclosed |
| WO-2012059933-A1 | A NEW PROCESS FOR PREPARING OPTICALLY PURE MILNACIPRAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS. | ARCH PHARMALABS LIMITED (IN) | 2012-05-10 | — | — | WO | disclosed |
| US-20100204486-A1 | Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes | MERCK & CO., INC. (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289744-A1 | PROCESS FOR PREPARING OPTICALLY PURE MILNACIPRAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | SLCO1B3, SLCO4C1, SLCO1B1 | PTGS2 3157/4885MAOB 634/4885HTR2A 949/4885 |
| US-20100204486-A1 | Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes | ADH1C, AVPR1B, HTR1B | PTGS2 3409/4885MAOB 14/4885HTR2A 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.